Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?

Endocrinology. 2021 Oct 1;162(10):bqab145. doi: 10.1210/endocr/bqab145.

Author

Abigail C Lay¹

Affiliation

¹ Bristol Renal, Bristol Medical School, University of Bristol, Bristol, BS1 3NY, UK.

No abstract available

Keywords: CVD; FFAR4; GPR120; atherosclerosis; cardiometabolic disease; diabetes; metabolic syndrome; obesity; vascular disease.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cardiovascular Diseases* / drug therapy
Humans
Obesity / drug therapy
Receptors, G-Protein-Coupled* / genetics

Substances

Receptors, G-Protein-Coupled